BridgeBio Adds Financial Runway Ahead Of Expected ATTR-CM Approval

Biotech gets $500m upon FDA approval in exchange for 5% sales royalty on acoramidis, which is expected to compete with Pfizer’s Vyndamax. The agreement also pushes debt payout to 2029.

Deferred debt
BridgeBio gains flexibility with debt deferral to 2029 • Source: Shutterstock

BridgeBio Pharma, Inc. believes it has a long-term blockbuster on its hands in acoramidis, a high-affinity stabilizer of transthyretin that has been filed for US approval in transthyretin amyloid cardiomyopathy (ATTR-CM), and now it has a pair of investors who appear to share that bullish sentiment. The Palo Alto, CA-based firm announced a set of transactions on 18 January that ultimately could bring it $1.25bn via a royalty agreement and a pair of financings.

Key Takeaways
  • BridgeBio sells a 5% royalty on ATTR-CM candidate acoramidis for $500m to two investors.

  • That deal plus an agreement to push back payment of...

BridgeBio filed a new drug application for acoramidis at the US Food and Drug Administration in November after a pair of positive Phase III data readouts in 2023 and expects...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.